(Q34561970)

English

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

venous thromboembolism

1 reference

based on heuristic

inferred from title

author name string

A G G Turpie

1

1 reference

Europe PubMed Central

3 August 2017

W D Fisher

2

1 reference

Europe PubMed Central

3 August 2017

K A Bauer

3

1 reference

Europe PubMed Central

3 August 2017

L M Kwong

4

1 reference

Europe PubMed Central

3 August 2017

M W Irwin

5

1 reference

Europe PubMed Central

3 August 2017

P Kälebo

6

1 reference

Europe PubMed Central

3 August 2017

F Misselwitz

7

1 reference

Europe PubMed Central

3 August 2017

M Gent

8

1 reference

Europe PubMed Central

3 August 2017

OdiXa-Knee Study Group

9

1 reference

Europe PubMed Central

3 August 2017

publication date

1 November 2005

1 reference

Europe PubMed Central

3 August 2017

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

3 August 2017

3

1 reference

Europe PubMed Central

3 August 2017

2479-2486

1 reference

Europe PubMed Central

3 August 2017

11

1 reference

Europe PubMed Central

3 August 2017

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

Ventilation-perfusion studies in suspected pulmonary embolism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01602.X

21 January 2018

Identifiers

10.1111/J.1538-7836.2005.01602.X

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34561970&oldid=1953896235"